Podjanee Jittamala on Muck Rack

Podjanee Jittamala

As seen in: The Lancet, medRxiv, eLife
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Podjanee

Contact Podjanee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19

|
By Podjanee Jittamala, Phrutsamon Wongnak, James Watson, Simon Boyd
| medRxiv
The authors have declared no competing interest. NCT05041907 Finding treatments for COVID-19: A phase 2 multi-centre adaptive platform trial to assess antiviral pharmacodynamics in early symptomatic COVID-19 (PLAT-COV) is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Open in Who Shared Issue with article?

Within-host modelling of primaquine-induced haemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers

|
By James Watson, Parinaz Mehdipour, Robert Moss, Podjanee Jittamala
| medRxiv
The authors have declared no competing interest. Thai Clinical Trial Registry: TCTR20170830002 and TCTR20220317004. This study was funded by the MRC "Assessing the tolerability of a potentially safer radical curative regimen of primaquine in healthy volunteers with glucose 6 phosphate dehydrogenase" (MR/R015252/1). This UK funded award is part of the EDCTP2 programme supported by the European Union. JAW is a Sir Henry Dale Fellow funded by the Wellcome Trust (223253/Z/21/Z).
Open in Who Shared View Duplicates (29) Issue with article?

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

|
By Podjanee Jittamala, Simon Boyd, Viravarn Luvira, Phrutsamon Wongnak
| The Lancet Verified
Research in context Evidence before this study Antiviral interventions can be assessed and compared using acceleration in the rate of viral clearance as a surrogate for clinical benefit. We searched PubMed for studies published in English from Jan 1, 2020, to Jan 3, 2024, using the terms: (SARS-CoV-2) AND (randomised) AND (antiviral) AND (viral clearance OR viral kinetics).
Open in Who Shared Issue with article?
See all 7 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified